BRCA-Monet: A breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database

BMC Systems Biology

Volumn 7, Issue SUPPL 5, 2013, Pages

  Ma, Chifeng ^a   Chen, Hung I H ^b   Flores, Mario ^a   Huang, Yufei ^a,b   Chen, Yidong ^b  

^a The University of Texas at San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast Cancer Mode of Action Network (BRCA MoNet); Connectivity Map; Mode of Action (MoA)

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; ANTINEOPLASTIC AGENT; ESTRADIOL; PYRAZOLE DERIVATIVE; TRIAZINE DERIVATIVE;

ARTICLE; BIOLOGY; BREAST TUMOR; GENETIC DATABASE; GENETICS; HUMAN; MCF 7 CELL LINE; METHODOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; ESTRADIOL; HUMANS; MCF-7 CELLS; PYRAZOLES; TREATMENT OUTCOME; TRIAZINES;

EID: 84889664768     PISSN: None     EISSN: 17520509     Source Type: Journal    
DOI: 10.1186/1752-0509-7-S5-S5     Document Type: Article

References (79)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360(8):790-800. 10.1056/NEJMra0801289, 19228622.
2. Riedel RF, et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008, 7(10):3141-9. 10.1158/1535-7163.MCT-08-0642, 18852117.
3. Schlueter PJ, Peterson RT. Systematizing serendipity for cardiovascular drug discovery. Circulation 2009, 120(3):255-63. 10.1161/CIRCULATIONAHA.108.824177, 2756982, 19620524.
4. Ebi H, et al. Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. Cancer Res 2009, 69(9):4027-35. 10.1158/0008-5472.CAN-08-3403, 19383916.
5. Hait WN, Hambley TW. Targeted cancer therapeutics. Cancer Res 2009, 69(4):1263-7. discussion 1267, 10.1158/0008-5472.CAN-08-3836, 19208830.
6. Garman KS, et al. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 2008, 105(49):19432-7. 10.1073/pnas.0806674105, 2592987, 19050079.
7. Yamashita T, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008, 68(5):1451-61. 10.1158/0008-5472.CAN-07-6013, 18316609.
8. Jia HL, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 2007, 13(4):1133-9. 10.1158/1078-0432.CCR-06-1025, 17317821.
9. Budhu A, et al. prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10(2):99-111. 10.1016/j.ccr.2006.06.016, 16904609.
10. Ye QH, et al. predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9(4):416-23. 10.1038/nm843, 12640447.
11. Kessel AGV. Large Scale Genome Variation in Health and Disease in: Cytogenetics and Genome Research. 2006, Nijmegen.
12. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007, 7(1):54-60. 10.1038/nrc2044, 17186018.
13. Lee JK, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007, 104(32):13086-91. 10.1073/pnas.0610292104, 1941805, 17666531.
14. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-50. 10.1073/pnas.0506580102, 1239896, 16199517.
15. Huang L, et al. An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One 2011, 6(7):e22274. 10.1371/journal.pone.0022274, 3137633, 21789246.
16. Cohen AL, et al. A pharmacogenomic method for individualized prediction of drug sensitivity. Mol Syst Biol 2011, 513.
17. Yeh CT, et al. Trifluoperazine an antipsychotic agent inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med 2012, 186(11):1180-8. 10.1164/rccm.201207-1180OC, 23024022.
18. Yuen HF, et al. TAZ Expression as a Prognostic Indicator in Colorectal Cancer. PLoS One 2013, 8(1):e54211. 10.1371/journal.pone.0054211, 3553150, 23372686.
19. Edris B, et al. Comparative gene expression profiling of benign and malignant lesions reveals candidate therapeutic compounds for leiomyosarcoma. Sarcoma 2012, 805614.
20. Reka AK, et al. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol 2011, 6(11):1784-92. 10.1097/JTO.0b013e31822adfb0, 3196823, 21964532.
21. Claerhout S, et al. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011, 6(9):e24662. 10.1371/journal.pone.0024662, 3170379, 21931799.
22. Lan MY, et al. From NPC therapeutic target identification to potential treatment strategy. Mol Cancer Ther 2010, 9(9):2511-23. 10.1158/1535-7163.MCT-09-0966, 20716640.
23. Lee HS, et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol 2012, 80.
24. Gottlieb A, et al. pREDICT: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 2011, 496.
25. Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS One 2009, 4(8):e6536. 10.1371/journal.pone.0006536, 2715883, 19657382.
26. Shats I, et al. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 2011, 71(5):1772-80. 10.1158/0008-5472.CAN-10-1735, 3049992, 21169407.
27. Jin G, et al. A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy. Cancer Res 2012, 72(1):33-44. 10.1158/0008-5472.CAN-11-2333, 3251651, 22108825.
28. Zhao C, et al. Identifying mechanistic similarities in drug responses. Bioinformatics 2012, 28(14):1902-10. 10.1093/bioinformatics/bts290, 22592382.
29. Shigemizu D, et al. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol 2012, 8(2):e1002347. 10.1371/journal.pcbi.1002347, 3276504, 22346740.
30. McArt DG, Zhang SD. Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. PLoS One 2011, 6(1):e16382. 10.1371/journal.pone.0016382, 3031567, 21305029.
31. Ma H, Zhao H. FacPad: Bayesian sparse factor modeling for the inference of pathways responsive to drug treatment. Bioinformatics 2012, 28(20):2662-70. 10.1093/bioinformatics/bts502, 3467747, 22923307.
32. Bulzomi P, et al. Naringenin and 17beta-estradiol coadministration prevents hormone-induced human cancer cell growth. IUBMB Life 2010, 62(1):51-60.
33. Inoue A, et al. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 2004, 32(3):649-61. 10.1677/jme.0.0320649, 15171706.
34. Drabsch Y, Robert RG, Gonda TJ. MYB suppresses differentiation and apoptosis of human breast cancer cells. Breast Cancer Res 2010, 12(4):R55. 10.1186/bcr2614, 2949644, 20659323.
35. Frasor J, et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006, 66(14):7334-40. 10.1158/0008-5472.CAN-05-4269, 16849584.
36. Greenway FL, Bray GA, Heber D. Topical fat reduction. Obes Res 1995, 3(Suppl 4):561S-568S.
37. Guo AJ, et al. Kaempferol as a flavonoid induces osteoblastic differentiation via estrogen receptor signaling. Chin Med 2012, 10.
38. Wang J, et al. Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist. FEBS Lett 2009, 583(4):643-7. 10.1016/j.febslet.2009.01.030, 19171140.
39. Hung H. Inhibition of estrogen receptor alpha expression and function in MCF-7 cells by kaempferol. Journal of Cellular Physiology 2004, 198(2):197-208. 10.1002/jcp.10398, 14603522.
40. Kim HJ, et al. Estrogen receptor alpha-induced cholecystokinin type A receptor expression in the female mouse pituitary. J Endocrinol 2007, 195(3):393-405. 10.1677/JOE-07-0358, 18000302.
41. Planas-Silva MD, Filatova IS. Estrogen-dependent regulation of Eg5 in breast cancer cells. Anticancer Drugs 2007, 18(7):773-9. 10.1097/CAD.0b013e3280a02f2b, 17581299.
42. Widdop B. Therapeutic drug monitoring. Contemporary issues in clinical biochemistry 1985, Edinburgh; New York: Churchill Livingstone.
43. Willemse PH, et al. Clinical and endocrine effects of cyproterone acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer Clin Oncol 1988, 24(3):417-21. 10.1016/S0277-5379(98)90011-6, 2968261.
44. Awasthi N, et al. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. Mol Cancer Ther 2012, 11(12):2644-53. 10.1158/1535-7163.MCT-12-0447, 23047891.
45. Lee SJ, et al. A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography. Invest New Drugs 2012,
46. Kolb EA, et al. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011, 56(4):595-603. 10.1002/pbc.22741, 21298745.
47. Carboni JM, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009, 8(12):3341-9. 10.1158/1535-7163.MCT-09-0499, 19996272.
48. Litzenburger BC, et al. High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines Correlates with Sensitivity to IGF-IR Inhibitor BMS-754807 in This Subtype of Human Breast Cancer. Cancer Research 2009, 69(24):581s-581s.
49. Tamura Y, et al. phase 1 Dose-Escalating Study of Bms-754807 in Japanese Patients with Advanced Solid Tumors. Annals of Oncology 2012, 111-112.
50. Kolb EA, et al. Initial Testing (Stage 1) of the IGF-1 Receptor Inhibitor BMS-754807 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2011, 56(4):595-603. 10.1002/pbc.22741, 21298745.
51. Chu QS, et al. BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors. Ejc Supplements 2010, 8(7):131-131.
52. Desai J, et al. Targeting Type I Insulin-Like Growth Factor Receptor and Insulin Receptor for Cancer Therapy: The Oral Dual Inhibitor Bms-754807 in Clinical Development. Annals of Oncology 2010, 9-9.
53. Macdonald RL, Bergey GK. Valproic acid: effect on GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons. Trans Am Neurol Assoc 1978, 254-6.
54. Duenas-Gonzalez A, et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 2008, 34(3):206-22. 10.1016/j.ctrv.2007.11.003, 18226465.
55. Michaelis M, Doerr HW, Cinatl J. Valproic acid as anti-cancer drug. Curr Pharm Des 2007, 13(33):3378-93. 10.2174/138161207782360528, 18045192.
56. Fortunati N, et al. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett 2008, 259(2):156-64. 10.1016/j.canlet.2007.10.006, 18006146.
57. Oh DS, et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. Journal of Clinical Oncology 2006, 24(11):1656-64. 10.1200/JCO.2005.03.2755, 16505416.
58. Macdonald F. Dictionary of pharmacological agents. 1997, London; Weinheim; New York: Chapman & Hall, 1 livret d'installation d'un cédérom.
59. Munster PN, et al. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin, sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Clin Cancer Res 2001, 7(8):2228-36.
60. Kitson RR, et al. Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem 2013, 5(4):307-14. 10.1038/nchem.1596, 23511419.
61. Onuoha SC, et al. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol 2007, 372(2):287-97. 10.1016/j.jmb.2007.06.065, 17662999.
62. Bellarosa D, et al. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol 2012, 41(4):1486-1494.
63. Fiskus W, et al. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Research and Treatment 2012, 135(2):433-444. 10.1007/s10549-012-2171-9, 22825030.
64. Uehara N, Yoshizawa K, Tsubura A. Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells. Oncology Reports 2012, 28(1):105-110.
65. Uehara N, et al. Requirement of p38 MAPK for a cell-death pathway triggered by vorinostat in MDA-MB-231 human breast cancer cells. Cancer Lett 2012, 315(2):112-121. 10.1016/j.canlet.2011.07.032, 22093617.
66. Wong NS, et al. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. Pharmacogenet Genomics 2011, 21(11):760-768. 10.1097/FPC.0b013e32834a8639, 21849928.
67. Munster PN, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 2011, 104(12):1828-1835. 10.1038/bjc.2011.156, 3111195, 21559012.
68. Zhou Q, et al. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 2010, 10(5):1029-1039. 3337220, 20049865.
69. Swaby RF, et al. A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. Cancer Research 2009, 69(24):793s-793s.
70. Palmieri D, et al. preclinical studies in support of the use of vorinostat (SAHA) for the treatment of brain metastases of breast cancer. Clinical & Experimental Metastasis 2009, 26(7):905-906.
71. Munster PN, et al. phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. Journal of Clinical Oncology 2009, 27(15).
72. Luu TH, Morgan RJ, Leong L. A Phase II Trial of Vorinostat in Metastatic Breast Cancer (vol 14, pg 7138, 2008). Clinical Cancer Research 2009, 15(1):416-416.
73. Luu TH, et al. A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study. Clinical Cancer Research 2008, 14(21):7138-7142. 10.1158/1078-0432.CCR-08-0122, 3543872, 18981013.
74. Vanhaecke T, et al. Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view. Current Medicinal Chemistry 2004, 11(12):1629-43. 10.2174/0929867043365099, 15180568.
75. Tavakoli-Yaraki M, et al. Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1. Tumour Biol 2013, 34(1):241-9. 10.1007/s13277-012-0544-7, 23055198.
76. Nakajima S, et al. Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231. Oncology Reports 2009, 22(1):143-8.
77. Alao JP, et al. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer 2006, 8.
78. Min KN, et al. Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells. Arch Pharm Res 2004, 27(5):554-61. 10.1007/BF02980131, 15202563.
79. Vigushin DM, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001, 7(4):971-6.